Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod
Infantile hemangiomas are the most common benign tumors of infancy, characterized by unregulated angiogenesis and endothelial cells with high mitotic rate. Although spontaneous regression occurs, sometimes treatment is required and alternatives to corticosteroids should be considered to reduce side...
| Autor principal: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
Elsevier Ireland Ltd
2018
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 14190caa a22016697a 4500 | ||
|---|---|---|---|
| 001 | PAPER-16940 | ||
| 003 | AR-BaUEN | ||
| 005 | 20240415150333.0 | ||
| 008 | 190410s2018 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-85042352134 | |
| 024 | 7 | |2 cas |a imiquimod, 99011-02-6; Aminoquinolines; Antineoplastic Agents; imiquimod | |
| 030 | |a TOLED | ||
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 100 | 1 | |a Rocco, R. | |
| 245 | 1 | 0 | |a Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod |
| 260 | |b Elsevier Ireland Ltd |c 2018 | ||
| 270 | 1 | 0 | |m Gazzaniga, S.; Laboratorio de Biología Tumoral, Dpto. de Química Biológica IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos AiresArgentina; email: sgazza@qb.fcen.uba.ar |
| 504 | |a Chen, T.S., Eichenfield, L.F., Friedlander, S.F., Infantile hemangiomas: an update on pathogenesis and therapy (2013) Pediatrics, 131 (1), pp. 99-108 | ||
| 504 | |a Mulliken, J.B., Glowacki, J., Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics (1982) Plast. Reconstr. Surg., 69 (3), pp. 412-422 | ||
| 504 | |a Bruckner, A.L., Frieden, I.J., Hemangiomas of infancy (2003) J. Am. Acad. Dermatol., 48, pp. 477-493 | ||
| 504 | |a Lo, K., Mihm, M., Fay, A., Current theories on the pathogenesis of infantile hemangioma (2009) Semin. Ophthalmol., 24, pp. 172-177 | ||
| 504 | |a Haggstrom, A.N., Drolet, B.A., Baselga, E., Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment (2006) Pediatrics, 118 (3), pp. 882-887 | ||
| 504 | |a Leonardi-Bee, J., Batta, K., O'Brien, C., Interventions for infantile haemangiomas (strawberry birthmarks) of the skin (2011) Cochrane Database Syst. Rev., 5, p. D006545 | ||
| 504 | |a Callahan, A.B., Yoon, M.K., Infantile hemangiomas: a review (2012) Saudi J. Ophthalmol., 26 (3), pp. 283-291 | ||
| 504 | |a Richter, G.T., Friedman, A.B., Hemangiomas and vascular malformations: current theory and management (2012) Int. J. Pediatr., 2012, pp. 1-10. , 645678 | ||
| 504 | |a Luu, M., Frieden, I.J., Haemangioma: clinical course, complications and management (2013) Br. J. Dermatol., 169, pp. 20-30 | ||
| 504 | |a Hoeger, P.H., Harper, J.I., Baselga, E., Treatment of infantile haemangiomas: recommendations of a European expert group (2015) Eur. J. Pediatr., 174 (7), pp. 855-865 | ||
| 504 | |a Holland, K.E., Frieden, I.J., Frommelt, P.C., Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma (2010) Arch. Dermatol., 146 (7), pp. 775-778 | ||
| 504 | |a De Graaf, M., Breur, J.M., Raphael, M.F., Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants (2011) J. Am. Acad. Dermatol., 65 (2), pp. 320-327 | ||
| 504 | |a Qayyum, S., Role of Propranolol in the management of periocular infantile hemangioma (2016) Pak. J. Ophthalmol., 32 (2), pp. 84-90 | ||
| 504 | |a Xiao, Q., Li, Q., Zhang, B., Yu, W., Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence (2013) Pediatr. Surg. Int., 29 (June (6)), pp. 575-581 | ||
| 504 | |a Martinez, M.I., Sanchez-Carpintero, I., North, P.E., Clinical resolution with 5% imiquimod cream (2002) Arch Dermatol. Infantile Hemangioma, 138, pp. 881-884 | ||
| 504 | |a Welsh, O., Olazaran, Z., Gomez, M., Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream (2004) J. Am. Acad. Dermatol., 51 (4), pp. 639-642 | ||
| 504 | |a Hazen, P.G., Carney, J.F., Engstrom, C.W., Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream (2005) Pediatr. Dermatol., 22, pp. 254-256 | ||
| 504 | |a Barry, R.B., Hughes, B.R., Cook, L.J., Involution of infantile haemangiomas after imiquimod 5% cream (2008) Clin. Exp. Dermatol., 33 (4), pp. 446-449 | ||
| 504 | |a Miller, R.L., Gerster, J.F., Owens, M.L., Imiquimod applied topically: a novel immune response modifier and new class of drug (1999) Int. J. Immunopharmacol., 21, pp. 1-14 | ||
| 504 | |a Tyring, S., Imiquimod applied topically: a novel immune response modifier (2001) Skin Therapy Lett., 6, pp. 1-4 | ||
| 504 | |a Kirtschig, G., van Meurs, T., van Doorn, R., Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate (2015) Acta Derm. Venereol., 95, pp. 83-85 | ||
| 504 | |a Mora, A.N., Karia, P.S., Nguyen, B.M., A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance (2015) J. Am. Acad. Dermatol., 73 (2), pp. 205-212 | ||
| 504 | |a Steinmann, A., Funk, J.O., Schuler, G., von den Driesch, P., Topical imiquimod treatment of a cutaneous melanoma metastasis (2000) J. Am. Acad. Dermatol., 43, pp. 555-556 | ||
| 504 | |a Beutner, K.R., Spruance, S.L., Hougham, A.J., Treatment of genital warts with an immune-response modifier (imiquimod) (1998) J. Am. Acad. Dermatol., 38, pp. 230-239 | ||
| 504 | |a Stockfleth, E., Lmax and imiquimod 3. 75%: the new standard in AK management (2015) J. Eur. Acad. Dermatol. Venereol., 29, pp. 9-14 | ||
| 504 | |a Gupta, G., Stockfleth, E., Peris, K., Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis (2015) J. Eur. Acad. Dermatol. Venereol., 9, pp. 1840-1842 | ||
| 504 | |a Hannuksela-Svahn, A., Nordal, E., Christensen, O.B., Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream (2000) Acta Derm. Venereol., 80 (5), pp. 381-382 | ||
| 504 | |a Marks, R., Gebauer, K., Shumack, S., Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial (2001) J. Am. Acad. Dermatol., 44 (5), pp. 807-813 | ||
| 504 | |a Sapijaszko, M.J., Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma (2005) Skin Ther. Lett., 10, pp. 2-5 | ||
| 504 | |a McCuaig, C.C., Dubois, J., Powell, J., A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma (2009) Pediatr. Dermatol., 26, pp. 203-212 | ||
| 504 | |a Jiang, C., Hu, X., Ma, G., A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma (2011) Pediatr. Dermatol., 28, pp. 259-266 | ||
| 504 | |a Vidal, D., Alomar, A., Mode of action and clinical use of imiquimod (2008) Expert Rev. Dermatol., 3 (2), pp. 151-159 | ||
| 504 | |a Kobold, S., Wiedemann, G., Rothenfußer, S., Modes of action of TLR7 agonists in cancer therapy (2014) Immunotherapy, 6 (10), pp. 1085-1095 | ||
| 504 | |a Rogge, L., Barberis-Maino, L., Biffi, M., Selective expression of an interleukin-12 receptor component by human T helper 1 cells (1997) J. Exp. Med., 185, pp. 825-831 | ||
| 504 | |a Weber, A., Zimmermann, C., Mausberg, A.K., Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod (2013) Int. Immunopharmacol., 17, pp. 427-431 | ||
| 504 | |a Garlanda, C., Parravicini, C., Sironi, M., Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors (1994) Proc. Natl. Acad. Sci. U. S. A., 91 (15), pp. 7291-7295 | ||
| 504 | |a Dong, Q.G., Bernasconi, S., Lostaglio, S., A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants (1997) Arterioscler. Thromb. Vasc. Biol., 17 (8), pp. 1599-1604 | ||
| 504 | |a Motulsky, H., Christopoulos, A., Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting (2004), Oxford University Press, Inc New York; Filippi-Chiela, E.C., Oliveira, M.M., Jurkovski, B., Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities (2012) PLoS One, 7 (8), p. e42522 | ||
| 504 | |a Kerr, J.F., Wyllie, A.H., Currie, A.R., Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics (1972) Br. J. Cancer, pp. 239-257 | ||
| 504 | |a Kroemer, G., Galluzzi, L., Vandenabeele, P., Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 (2009) Cell Death Differ., 16 (1), pp. 3-11 | ||
| 504 | |a Schön, M., Bong, A.B., Drewniok, C., Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod (2003) J. Natl. Cancer Inst., 95 (15), pp. 1138-1149 | ||
| 504 | |a Schön, M.P., Wienrich, B.G., Drewniok, C., Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod (2004) J. Invest. Dermatol., 122 (5), pp. 1266-1276 | ||
| 506 | |2 openaire |e Política editorial | ||
| 520 | 3 | |a Infantile hemangiomas are the most common benign tumors of infancy, characterized by unregulated angiogenesis and endothelial cells with high mitotic rate. Although spontaneous regression occurs, sometimes treatment is required and alternatives to corticosteroids should be considered to reduce side effects. Imiquimod is an imidazoquinoline, approved for some skin pathologies other than hemangioma. It is proposed that the effectiveness of imiquimod comes from the activation of immune cells at tumor microenvironment. However, the possibility to selectively kill different cell types and to directly impede angiogenesis has been scarcely explored in vitro for endothelial cells. In this work we showed a dramatic cytotoxicity on hemangioma cell, with a significant lower IC50 value in hemangioma compared to normal endothelial cells and melanoma (employed as a non-endothelial tumor cell line). Nuclear morphometric and flow-cytometry assays revealed imiquimod-induced apoptosis on hemangioma and melanoma cells but a small percentage of senescence on normal endothelial cells. At sub-lethal conditions, cell migration, a key step in angiogenesis turned out to be inhibited in a tumor-selective manner along with actin cytoskeleton disorganization on hemangioma cells. Altogether, these findings pointed out the selective cytotoxic effects of imiquimod on transformed endothelial cells, evidencing the potential for imiquimod to be a therapeutic alternative to reduce extensive superficial hemangioma lesions. © 2018 Elsevier B.V. |l eng | |
| 536 | |a Detalles de la financiación: Secretaría de Ciencia y Técnica, Universidad de Buenos Aires, 20020130200082BA | ||
| 536 | |a Detalles de la financiación: This work was supported by grants from CONICET and University of Buenos Aires, UBACYT 20020130200082BA . We would like to thank Dr. Adriana Cochón for providing assistance in statistical analysis of cytotoxicity assays. Appendix A | ||
| 593 | |a Laboratorio de Biología Tumoral, Dpto. de Química Biológica IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina | ||
| 593 | |a Institute of Experimental Medicine (IMEX) -CONICET, National Academy of Medicine, Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a CYTOTOXICITY |
| 690 | 1 | 0 | |a ENDOTHELIUM |
| 690 | 1 | 0 | |a HEMANGIOMA |
| 690 | 1 | 0 | |a IMIQUIMOD |
| 690 | 1 | 0 | |a IMIQUIMOD |
| 690 | 1 | 0 | |a AMINOQUINOLINE DERIVATIVE |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENT |
| 690 | 1 | 0 | |a IMIQUIMOD |
| 690 | 1 | 0 | |a ACTIN FILAMENT |
| 690 | 1 | 0 | |a ANGIOGENESIS |
| 690 | 1 | 0 | |a ANIMAL CELL |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CAPILLARY HEMANGIOMA |
| 690 | 1 | 0 | |a CELL MIGRATION |
| 690 | 1 | 0 | |a CELL TRANSFORMATION |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DRUG CYTOTOXICITY |
| 690 | 1 | 0 | |a DRUG SELECTIVITY |
| 690 | 1 | 0 | |a ENDOTHELIUM CELL |
| 690 | 1 | 0 | |a FLOW CYTOMETRY |
| 690 | 1 | 0 | |a HEMANGIOMA CELL |
| 690 | 1 | 0 | |a IC50 |
| 690 | 1 | 0 | |a IMMUNOCOMPETENT CELL |
| 690 | 1 | 0 | |a IMMUNOSTIMULATION |
| 690 | 1 | 0 | |a IN VITRO STUDY |
| 690 | 1 | 0 | |a MELANOMA CELL LINE |
| 690 | 1 | 0 | |a MORPHOMETRY |
| 690 | 1 | 0 | |a MOUSE |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a STRESS FIBER |
| 690 | 1 | 0 | |a TUMOR CELL |
| 690 | 1 | 0 | |a TUMOR MICROENVIRONMENT |
| 690 | 1 | 0 | |a ANIMAL |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a CELL AGING |
| 690 | 1 | 0 | |a CELL MOTION |
| 690 | 1 | 0 | |a CELL NUCLEUS |
| 690 | 1 | 0 | |a CELL SURVIVAL |
| 690 | 1 | 0 | |a CYTOSKELETON |
| 690 | 1 | 0 | |a DRUG EFFECTS |
| 690 | 1 | 0 | |a EXPERIMENTAL MELANOMA |
| 690 | 1 | 0 | |a HEMANGIOMA |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a PATHOLOGY |
| 690 | 1 | 0 | |a SKIN TUMOR |
| 690 | 1 | 0 | |a TUMOR CELL LINE |
| 690 | 1 | 0 | |a ULTRASTRUCTURE |
| 690 | 1 | 0 | |a AMINOQUINOLINES |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENTS |
| 690 | 1 | 0 | |a APOPTOSIS |
| 690 | 1 | 0 | |a CELL LINE, TUMOR |
| 690 | 1 | 0 | |a CELL MOVEMENT |
| 690 | 1 | 0 | |a CELL NUCLEUS |
| 690 | 1 | 0 | |a CELL SURVIVAL |
| 690 | 1 | 0 | |a CELLULAR SENESCENCE |
| 690 | 1 | 0 | |a CYTOSKELETON |
| 690 | 1 | 0 | |a ENDOTHELIAL CELLS |
| 690 | 1 | 0 | |a HEMANGIOMA |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a MELANOMA, EXPERIMENTAL |
| 690 | 1 | 0 | |a MICE |
| 690 | 1 | 0 | |a SKIN NEOPLASMS |
| 690 | 1 | 0 | |a STRESS FIBERS |
| 700 | 1 | |a Alegre, N. | |
| 700 | 1 | |a Pozner, R. | |
| 700 | 1 | |a Wainstok, Rosa | |
| 700 | 1 | |a Gazzaniga, S. | |
| 773 | 0 | |d Elsevier Ireland Ltd, 2018 |g v. 288 |h pp. 82-88 |p Toxicol. Lett. |x 03784274 |w (AR-BaUEN)CENRE-42 |t Toxicology Letters | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042352134&doi=10.1016%2fj.toxlet.2018.01.016&partnerID=40&md5=5712305ce288e7828d3c3d7417ac4842 |x registro |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.toxlet.2018.01.016 |x doi |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_03784274_v288_n_p82_Rocco |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03784274_v288_n_p82_Rocco |x registro |y Registro en la Biblioteca Digital |
| 961 | |a paper_03784274_v288_n_p82_Rocco |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||